-
2022-502917-27-00
5
2023-03-07
Migraine
-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia
-
2024-510656-13-00
5
2022-11-08
Migraine
-
2023-508425-28-00
4
2022-10-24
Chronic Inflammatory Demyelinating Polyneuropathy
-
2023-503442-30-00
5
2022-10-14
Multiple Myeloma
-
2024-512382-13-00
5
2022-10-04
Migraine (with or without aura)
-
2023-508868-30-00
5
2022-09-26
Treatment of stereotypical prolonged seizure
-
2023-507699-38-00
5
2022-08-30
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2024-510950-29-00
5
2022-07-21
Stereotypical prolonged seizure
-
2022-502646-27-00
10
2022-06-24
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
-
2023-506791-27-00
5
2022-04-22
pulmonary arterial hypertension
-
2024-518685-27-00
5
2022-03-22
acute/decompensated heart failure
-
2023-505438-85-00
5
2022-01-12
Acute myocardial infarction (AMI)
-
2024-515058-26-00
5
2021-12-17
NEPHROTIC SYNDROME
-
2023-504152-97-00
5
2021-11-26
Generalized Myasthenia Gravis
-
2023-507372-42-00
4
2021-09-20
Schizophrenia
-
2024-512982-15-00
5
2021-06-28
BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metas
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2023-507885-21-00
4
2020-08-18
Chronic Inflammatory Demyelinating Polyneuropathy
-
2024-519237-34-00
10
2019-11-26
Treatment for Refractory Schizophrenia in Adults
-
2023-507149-27-00
5
2019-11-04
Chemotherapy-induced Thrombocytopenia in Adult subjects with Non-small
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2025-521067-13-00
5
2026-04-24
Atherosclerotic Cardiovascular Disease (ASCVD)